Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans

Journal of the National Medical Association(2023)10.1016/j.jnma.2023.01.008Source: DataRank Database

Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans is a research paper published in Journal of the National Medical Association (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

refsnp doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.68)OA: hybridTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

David L. DeRemer ORCID,Esther Frimpong ORCID,Edward Agyare ORCID,John M. Allen ORCID,Luisel Ricks‐Santi ORCID

Live enrichment

PubMed:36801148 PMC:PMC10639003 OpenAlex:https://openalex.org/W4321213513

NCI NIH HHS

Grant: U54 CA233444

NCI NIH HHS

Grant: U54 CA233396

NCI NIH HHS

Grant: U54 CA233465

National Institutes of Health

Grant: 5U54CA233396-03

1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center

National Institutes of Health

Grant: 3U54CA233465-03S2

Impact of COVID-19 on cancer care delivery among diverse populations

National Institutes of Health

Grant: 1U54CA233444-01

2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center

National Cancer Institute

National Institutes of Health

FWCI

0.68

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jnma.2023.01.008

HYBRIDhttps://doi.org/10.1016/j.jnma.2023.01.008

publisherhttps://doi.org/10.1016/j.jnma.2023.01.008

publisherhttps://api.elsevier.com/content/article/PII:S0027968423000172?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0027968423000172?httpAccept=text/plain

Fields of Study

Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsLung Cancer Research StudiesMedicine0301 basic medicine03 medical and health sciences0302 clinical medicineHumansAntineoplastic AgentsBlack or African AmericanCarcinoma, Pancreatic DuctalPancreatic NeoplasmsPharmacogeneticsMolecular Targeted Therapy

MeSH Terms

Antineoplastic AgentsBlack or African AmericanHumansPancreatic NeoplasmsPharmacogeneticsCarcinoma, Pancreatic DuctalMolecular Targeted Therapy

Keywords

PharmacogeneticsMedicinePancreatic cancerGemcitabinePharmacogenomicsOncologyCancerGenetic predispositionGenetic testingInternal medicinePharmacologyGenotypeGeneticsBiologyGeneDiseaseDpd(5)Disparities(2)Equity(6)Pancreatic Cancer(3)Pharmacogenetics(1)Ugt1a1(4)Black or African AmericanPancreatic NeoplasmsHumansAntineoplastic AgentsMolecular Targeted TherapyArticleCarcinoma, Pancreatic Ductal

Sustainable Development Goals

SDG 0: Good health and well-being

Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans

FAIR Checklist

Authors (9)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)